

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Complete If Known				
Application Number	10/565,238			
Filing Date	January 19, 2006			
First Named Inventor	Pnina FISHMAN			
Confirmation No.	9164			
Art Unit	Not Yet Known			
Attomey Docket Number	FISHMAN=19B			

			U.S. PAT	ENT DOCUMENTS	
xaminer nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2004/229246 A1	11-18-2004	Pnina FISHMAN et al.	
	AB	US-2004/0137477 A1	07-15-2004	Pnina FISHMAN et al.	
	AC	US-2004/016709 A1	01-29-2004	FELCMAN et al.	
		US-			

		FORE	IGN PATENT DO	DCUMENTS		
Examiner nitials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т°
	AD	WO 2005/0063246 A1	07-14-2005	CAN-FITE BIOPHARMA LTD.		
	ΑE	WO 2004/086034 A	10-07-2004	BAYER HEALTHCARE AG		
						_
						_
	-					_
	_		+			-

Examiner Signature	/Satyendra Singh/	Date Considered	09/27/2008
-----------------------	-------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /SS/

*EXAMINET: Initial if inference considered, whether or not clateron is inconformance with the DEP (89). Down line through citation if not incommence and no considerant. Include copy of this form with next commissionation is applicant. *Applicant's unique citation designation making registeral. *See Wide Coder of USPYTO Pleaser Downward for Coder of USPYTO Pleaser Downward for Coder of USPYTO Pleaser Downward for Coder of USPYTO Pleaser Downward, the Principles of the September and the Coder of USPYTO Pleaser Downward, the Principles of the September and present the see asked in number of the patient of Coderward in Vision of the Empower makes present the see asked in number of the patient of Coderward in Vision of Coderward in Vision of Coderward in Vision (Indiana) and the Vision of Coderward in Vision (Indiana) and the Vision of Coderward in Vision (Indiana) and the Vision of Coderward in Vision (Indiana) and Vision (

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/565,238			
Filing Date	January 19, 2006			
First Named Inventor	Pnina FISHMAN			
Group Art Unit	9164			
Examiner Name	Not Yet Known			
Attomey Docket Number	FISHMAN=19B			

Sheet	t 2_	ot	f 2	Attorney Docke	t Number F	ISHMAN=19B	
		NON P	ATENT LITERATUR	E DOCUMENTS	OTHER INF	FORMATION	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
	AF	B. A. WALKER et al., "Adenosine A3 receptor expression and function in eosinophils", <u>American Journal of Respiratory Cell and Molecular Biology</u> , Vol. 16, No. 5, pages 531-537, May 1997.					
	AG P. G. BARALDI et al., "A3 Adenosine Receptor Ligands: History and Perspectives", <u>Medicinal Research Review</u> Vol. 20, No. 2, pages 103-128, March 2000.						<u>/s</u> ,
	AH Y. KOHNO et al., "Activation of A3 Adenosine Receptors on Human Eosinophils Elevates Intracellular Calcium Blood, Vol. 88, No. 9, pages 3569-3574, November 1, 1996.						
	AI		Evidence for involvement ncogene, Vol. 21, pages			-MECA mediated suppression of	
	AJ		"Targeting the A3 aden nist", Anticancer Res.,			inhibition of Prostate carcinoma o	ell
	AK	L. MADI et al., "A3 a growth inhibition", <u>J.</u>	denosine receptor activ Bio. Chem., Vol. 278,	vation in melanom pages 42121-4213	a cells: associati 30, 2003.	ion between receptor fate and turn	ior
	AL	G. OHANA et al., "Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist IB-CF101", <u>British J. Cancer.</u> Vol. 89, pages 1552-1558, 2003.					
	АМ	P. FISHMAN et al., "An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κP", <u>Oncogene</u> , Vol. 23, pages 2465-2471, 2004.					
	AN	C. SZABO et al., "Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists", <u>British J. Pharmacology</u> , Vol. 125, pages 379-387, 1998.					
	AO	J. MABLEY et al., "The adenosine A ₃ receptor agonist, N*4(3-iodobenzyl)-adenosine -5*N-methyluronamide, is protective in two murine models of collitis", <u>European J. Pharmacology</u> , Vol. 466, pages 323-329, 2003.					
-	AP	E. BAHARAV et al., "The effect of adenosine and the A ₃ adenosine receptor agonist IB-MECA on joint inflammation and autoimmune diseases models", https://linkr.j.html , Vol. 10 (supplement 1), page \$104, abstract 499, 2002.					act
AQ M. MONTESINOS et al., "Adenosine A _{3x} or A ₃ receptors are required for inhibition of inflammation by methotrexate and its analog MX-66", <u>Arthritis & Rheumatism</u> , Vol. 48, pages 240-247, 2003. AR L. MADI et al., "The A3 Adenosine Receptor is Highly Expressed in Turnor vs. Normal Cells: Potential Targe Turnor Growth Inhibition", <u>Clinical Cancer Research</u> , Vol. 10, pages 4472-4479, 2004.							
						s. Normal Cells: Potential Target fo 79, 2004.	or
	AS S. GESSI et al., "Elevated expression of A ₃ adenosine receptors in human colorectal cancer is reflected in peripheral blood cells", <u>Clinical Cancer Research</u> , Vol. 10, pages 5895-5901, 2004.						
Examir		/Satyendra	a Singh/	-	Date Considered	09/27/2008	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SS/

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.